ALB and infection: Further optimization of LpxC inhibitors (i.e., the prolongation of in vivo half-lives and the reduction of serum-albumin-binding capacities) may ultimately yield a clinically safe drug for the treatment of infections caused by currently resistant “professional” or opportunistic Gram-negative pathogens.